Anavex Life Sciences (STU:12X1) Float Percentage Of Total Shares Outstanding : 96.94% (As of May. 24, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Anavex Life Sciences's float shares is 82.05 Mil. Anavex Life Sciences's total shares outstanding is 84.64 Mil. Anavex Life Sciences's float percentage of total shares outstanding is 96.94%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Anavex Life Sciences's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Anavex Life Sciences's Institutional Ownership is 26.70%.

Anavex Life Sciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Anavex Life Sciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	82.05	/	84.64
	=	96.94%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences (STU:12X1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

AVXL:USA 12X1:Germany

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences (STU:12X1) Headlines

No Headlines